Combination of | |
---|---|
Efavirenz | Non-nucleoside reverse transcriptase inhibitor |
Lamivudine | Nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleoside reverse transcriptase inhibitor |
Clinical data | |
Trade names | Symfi, Symfi Lo |
Other names | EFV/3TC/TDF |
AHFS/ Drugs.com | Professional Drug Facts |
MedlinePlus | a618028 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [1] [2] [3] It combines efavirenz, lamivudine, and tenofovir disoproxil. [3] As of 2019 [update], it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir. [4] It is taken by mouth. [1] [2] [3]
Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness. [3] Severe side effects may include depression, psychosis, or osteonecrosis. [3] In those with a history of epilepsy, it may increase the frequency of seizures. [3] Greater care should also be taken in those with kidney problems. [3] Its use during pregnancy appears to be unsafe. [1] [2]
It is on the World Health Organization's List of Essential Medicines. [5] The combination received tentative approval in the United States in 2014, [6] and was granted approval in February 2018. [7] [8] Its availability and importance is supported by Medecins Sans Frontieres. [3] It is available as a generic medication. [9] [10] [11]
Combination of | |
---|---|
Efavirenz | Non-nucleoside reverse transcriptase inhibitor |
Lamivudine | Nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleoside reverse transcriptase inhibitor |
Clinical data | |
Trade names | Symfi, Symfi Lo |
Other names | EFV/3TC/TDF |
AHFS/ Drugs.com | Professional Drug Facts |
MedlinePlus | a618028 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [1] [2] [3] It combines efavirenz, lamivudine, and tenofovir disoproxil. [3] As of 2019 [update], it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir. [4] It is taken by mouth. [1] [2] [3]
Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness. [3] Severe side effects may include depression, psychosis, or osteonecrosis. [3] In those with a history of epilepsy, it may increase the frequency of seizures. [3] Greater care should also be taken in those with kidney problems. [3] Its use during pregnancy appears to be unsafe. [1] [2]
It is on the World Health Organization's List of Essential Medicines. [5] The combination received tentative approval in the United States in 2014, [6] and was granted approval in February 2018. [7] [8] Its availability and importance is supported by Medecins Sans Frontieres. [3] It is available as a generic medication. [9] [10] [11]